Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 9/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.42 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873479 | 0.80 | AGTR1 (0.52) | LPLLIPGAGTR1AGTR2 | |
| SCHEMBL8260760 | 0.79 | AGTR1 (0.48) | AGTR1AGTR2ABCC3ABCC2 | |
| SCHEMBL951175 | 0.77 | AGTR1 (0.66) | AGTR1AGTR2ABCC3ABCC2 | |
| SCHEMBL946900 | 0.74 | AGTR1 (0.67) | AGTR1AGTR2 | |
| SCHEMBL7995850 | 0.74 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL8507705 | 0.73 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL27406325 | 0.72 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL21083902 | 0.72 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL9598348 | 0.72 | AGTR1 (0.50) | AGTR1AGTR2 | |
| SCHEMBL27403298 | 0.72 | AGTR1 (0.48) | AGTR1AGTR2ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11407733-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| EP-1844019-B1 | METHODE FOR THE PRODUCTION OF LOSARTAN | RATIOPHARM GMBH (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-2080756-A2 | Method for making losartan | Ratiopharm GmbH (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20090111994-A1 | Method for The Production of Losartan | RATIOPHARM GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111994-A1 | Method for The Production of Losartan | RATIOPHARM GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2006081807-A2 | METHOD FOR THE PRODUCTION OF LOSARTAN | RATIOPHARM GMBH (DE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407733-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | LPL 3432/4885LIPG 2418/4885AGTR1 7/4885 |
| US-20090111994-A1 | Method for The Production of Losartan | AGTR1, REN, AGTR2 | LPL 820/4885LIPG 1081/4885AGTR1 1/4885 |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | LPL 3432/4885LIPG 2418/4885AGTR1 7/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | LPL 3432/4885LIPG 2418/4885AGTR1 7/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | LPL 3432/4885LIPG 2418/4885AGTR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.